Skip to main content

Table 1 Comparative concentrations of bacteria on blood, endotoxins (LPS), malondialdehyde (MDA) and tumor necrosis factor-alpha (TNFα) of groups of treatment. Therapy was administered 1.5 hours after bacterial challenge.

From: Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa

Time (hours) after bacterial challenge

A (controls)

B (clarithromycin)

C (amikacin)

D (clarithromycin + amikacin)

 

Bacteria in blood (Mean ± SE, log10 cfu/ml)

1.5

1.72 ± 0.31

2.53 ± 0.61

1.92 ± 0.23

2.00 ± 0.75

3.5

1.95 ± 0.26

2.05 ± 0.36

2.22 ± 0.36

1.20 ± 0.20

24

3.35 ± 1.23

4.91 ± 0.99

6.24 ± 0.76

3.72 ± 0.89

48

5.93 ± 1.06

5.94 ± 1.06

5.23 ± 1.77

5.13 ± 0.93

 

LPS (Mean ± SE, EU/ml)

1.5

10.79 ± 7.28

4.53 ± 1.94

10.15 ± 6.87

5.88 ± 2.68

3.5

1.17 ± 0.54

6.25 ± 2.94a

10.02 ± 6.72

3.92 ± 0.73

24

7.35 ± 2.02

11.09 ± 4.87

9.88 ± 3.72

36.22 ± 5.52

48

21.86 ± 16.42

3.00 ± 1.24

4.81 ± 2.79

8.11 ± 6.97

 

MDA (Mean ± SE, μmol/l)

0

2.56 ± 0.26

3.02 ± 0.88

2.18 ± 0.78

1.50 ± 0.39

1.5

2.52 ± 1.05

4.57 ± 1.33

3.48 ± 1.48

1.87 ± 0.52

3.5

3.19 ± 1.06

4.54 ± 1.26

2.09 ± 1.22

1.29 ± 0.26

24

3.74 ± 1.00

1.71 ± 0.73b

2.72 ± 2.24

1.89 ± 0.53

48

1.75 ± 0.53

3.13 ± 1.44

3.86 ± 2.79

4.77 ± 3.68

 

TNFα (Mean ± SE, pg/ml)

0

18.91 ± 4.95

21.98 ± 8.04

21.99 ± 4.71

22.50 ± 9.09

1.5

34.53 ± 15.55

11.57 ± 0.08

40.96 ± 23.29

113.67 ± 55.52

3.5

43.72 ± 27.02

17.33 ± 5.82

643.85 ± 609.53

31.77 ± 20.51

24

20.81 ± 11.71

248.82 ± 226.51

29.46 ± 17.96

60.49 ± 50.65

48

977,62 ± 97,63

32.81 ± 13.23

18.11 ± 6.61

47.53 ± 26.46

  1. P of comparisons to group A: a0.042, b0.032